Competitor Analysis: EGF-R Antibodies 2015 - Biosuperiors and Biosimilars of Erbitux; New Report Launched

This Competitive Intelligence Report about EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux provides a competitor evaluation in the field of recombinant antibodies targeting epithelial growth factor receptor (EGF-R) to treat solid tumors as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of solid tumors. In addition, the report lists company-specific R&D pipelines of EGF-R antibodies. Competitor projects are listed in a tabular format providing information on:

• Drug Codes,
• Target / Mechanism of Action,
• Class of Compound,
• Company,
• Product Category,
• Indication,
• R&D Stage and
• additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Spanning over 50 pages, “Competitor Analysis: EGF-R Antibodies 2015 – Biosuperiors and Biosimilars of Erbitux” report covers the 2014 Sales of EGF-R Antibodies, Marketed EGF-R Antibodies, EGF-R Antibody Biosuperiors, EGF-R Antibody Biosimilars, Corporate Biosuperior & Biosimilar EGF-R Antibody Pipelines.

For further information on this report, please visit- http://mrr.cm/4gZ

Find all Biotechnology Reports at: http://www.marketresearchreports.com/biotechnology